Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...

For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free ...

The following is a summary of "Preoperative Chemoradiotherapy for Resectable Gastric Cancer," published in the September 2024 ...

New data from landmark analysis presented today reports a decreased risk of disease recurrence or death in patients with ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

Pheochromocytoma tumor size was linked to symptom presentation, as large vs small tumors showed more signs of catecholamine excess.

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible ...

Researchers found that proton pump inhibitors (PPIs) taken during the perioperative period in total hip arthroplasty (THA) ...

The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.